Abstract:Purpose: Liver fibrosis is a major cause of morbidity and mortality and the outcome of various chronic liver diseases. Activation of hepatic stellate cells (HSCs) is the key event in liver fibrosis. Studies have confirmed that miR-140-3p plays a potential regulatory effect on HSC activation. However, whether miR-140-3p mediates the liver fibrosis remains unknown. Materials and Methods: Expression of miR-140-3p was detected by real-time quantitative PCR (qPCR). Cell proliferation was measured by MTT, while cell apoptosis rate was determined via flow cytometry. Western blot assay was used to detect the expression of cleaved PARP. The fibrogenic effect was evaluated by expression of alpha-smooth muscle actin and desmin. Functional experiments were performed in transforming growth factor beta 1 (TGF-beta 1)-induced HSC-T6 cells with transfection of anti-miR-140-3p and/or siPTEN. Target binding between miR-140-3p and PTEN was predicted by the TargetScan database and identified using luciferase reporter assay and RNA immunoprecipitation. Results: TGF-beta 1 induced the activation of HSC-T6 cells, and miR-140-3p expression varied according to HSC-T6 cell activation status. Knockdown of miR-140-3p reduced cell proliferation and the expressions of alpha-SMA and desmin, as well as increased apoptosis, in TGF-beta 1-induced HSC-T6 cells, which could be blocked by PTEN silencing. Additionally, inactivation of the AKT/mTOR signaling pathway stimulated by miR-140-3p knockdown was abolished when silencing PTEN expression. PTEN was negatively regulated by miR-140-3p via direct binding in HSC-T6 cells. Conclusion: miR-140-3p is an important mediator in HSC-T6 cell activation, and miR-140-3p knockdown suppresses cell proliferation and fibrogenesis in TGF-beta 1-induced HSC-T6 cells, indicating that miR-140-3p may be a potential novel molecular target for liver fibrosis.

TET3 Mediates the Activation of Human Hepatic Stellate Cells Via Modulating the Expression of Long Non-Coding RNA HIF1A-AS1.

DNA Methylation of PTGIS Enhances Hepatic Stellate Cells Activation and Liver Fibrogenesis.

TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation

Inhibitory Effects of Long Noncoding RNA MEG3 on Hepatic Stellate Cells Activation and Liver Fibrogenesis.

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells

Wnt5a Promotes Cytokines Production and Cell Proliferation in Human Hepatic Stellate Cells Independent of Canonical Wnt Pathway.

Mir-488-5p Mitigates Hepatic Stellate Cell Activation and Hepatic Fibrosis Via Suppressing TET3 Expression

TLX3 Repressed SNAI1-induced Epithelial-Mesenchymal Transition by Directly Constraining STAT3 Phosphorylation and Functionally Sensitized 5-FU Chemotherapy in Hepatocellular Carcinoma

The M6a Methyltransferase Mettl3 Deficiency Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis

The Expression of TET3 Regulated Cell Proliferation in HepG2 Cells

LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212

Therapeutic potential of tLyp-1-EV-shCTCF in inhibiting liver cancer stem cell self-renewal and immune escape via SALL3 modulation in hepatocellular carcinoma

DNMT3a-mediated methylation of TCF21/hnRNPA1 aggravates hepatic fibrosis by regulating the NF-κB signaling pathway

Experimental Study of Proliferation and Activation of HSC-T6cells Through RNA Inference Targeting MeCP2

Knockdown of TRIM15 Inhibits the Activation of Hepatic Stellate Cells.

Mir-140-3p Knockdown Suppresses Cell Proliferation and Fibrogenesis in Hepatic Stellate Cells Via PTEN-Mediated AKT/mTOR Signaling.

Down-regulation of Ttg Expression by RNAi Inhibits HSC Proliferation and Attenuates Liver Fibrosis.

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis